Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1218330

Cover Image

PUBLISHER: Arizton Advisory & Intelligence | PRODUCT CODE: 1218330

Europe Monkeypox Testing Market - Industry Outlook and Forecast 2023-2025

PUBLISHED:
PAGES: 159 Pages
DELIVERY TIME: 1-2 business days
SELECT AN OPTION
PDF (Single User License)
USD 3500
PDF (5 User License)
USD 3995
PDF (Corporate User License)
USD 4995

Add to Cart

The Europe monkeypox testing market was valued at USD 18,330.00 thousand in 2022 and is expected to reach USD 56.10 thousand by 2025.

KEY MARKET INSIGHTS

  • Syndromic tests for monkeypox detection are expected to witness strong growth because they can distinguish monkeypox from other harmful diseases, allowing for easier treatment. On 25th May 2022, Roche and its subsidiary TIB Molbiol announced that they had developed a unique LightMix Modular Virus kit that simultaneously detects orthopoxvirus and offers information on whether an MPXV is present or not, including all MPXV from both the West African and Central African forms of the virus.
  • Rapid tests in the Europe monkeypox testing market are also expected to witness strong growth due to their rapid results and increasing consumer preference.
  • Demand for MPXV testing kits is expected to decline during the forecast as the cases can be seen declining due to increased surveillance, contact tracing, and increasing vaccination across Europe.

Increasing cases and testing are driving the growth of the Europe monkeypox testing market. The growing development of PCR kits as a standard gold method for monkeypox virus detection is propelling the growth of the market in the country. Also, increasing collaborations among In-Vitro Diagnostic (IVD) companies to develop and launch new monkeypox test kits is driving market growth. Surprisingly, the ease in medical device regulation only specific for monkeypox encouraged the IVD companies to bring new testing kits into the market and commercialize it, with PCR kits being the gold standard method. Confirmation of MPXV infection is based on nucleic acid amplification testing (NAAT), which uses conventional or real-time PCR to detect unique viral DNA sequences and is widely used as a standard method to detect MPXV. Increasing activities among vendors are driving the Europe monkeypox testing market growth, including the following:

  • In July 2022, ELITechGroup, a France-based privately held manufacturer and distributor of IVD equipment, strategically partnered with Jiangsu Bioperfectus Technologies for monkeypox virus testing across Europe.
  • In June 2022, Eurobio Scientific launched a CE-marked monkeypox screening test available for hospital use in France.
  • On 8th June 2022, altona Diagnostics, a medical diagnostic company headquartered in Germany, announced the launch of the RealStar Zoonotic Orthopoxvirus PCR Kit 1.0, a real-time RT-PCR based reagent system for the detection of zoonotic (non-variola) Orthopoxvirus species-specific DNA - including MPVX DNA of the Central and West African strains.
  • On 27th June 2022, Cepheid collaborated with the UK-based global molecular diagnostics company BioGX and announced a partnership between the two companies to provide a PCR test for MPX that will run on the GeneXpert system.
  • In July, the altona Diagnostics company launched another monkeypox virus detection kit, Flexstar Monkeypox virus PCR Detection Mix 1.5, for research purposes.
  • Bioactiva Diagnostica is another Germany-based company that offers PCR kits for monkeypox virus detection.

SEGMENT ANALYSIS

The growing product launches of lateral flow assay kits are expected to create lucrative opportunities for the Europe monkeypox testing market growth. Lateral flow assay is presently not preferred for monkeypox detection in the region because it may give false positive and negative results and because of its high cost. A number of rapid antibody and antigen test kits has been developed. Nanjing Synthgene Medical Technology, a China-based biomedical company, offers CE-certified rapid antibody and antigen tests at USD 1,253 and USD 438, respectively. In contrast, its MPXV Detection Kit (RT-PCR) costs around USD 144 with 24 tests, which means about USD 6 for each test.

Segmentation By Type

  • PCR
  • Lateral Flow Assay
  • Others

The growing surveillance, contact tracing, and vaccine doses across the region are expected to impede market growth by a greater margin. However, it is unclear how much vaccine administrations have contributed to the slowdown in case numbers, and it is also unclear how long vaccine effects will last. In July 2022, the European Commission approved the MPX preventative vaccine, recommended by the European Medicines Agency (EMA).

Segmentation By End-User

  • Laboratories
  • Hospitals & Clinics
  • Others

Bavarian Nordic, a global leader in smallpox vaccines, has been a long-term supplier of the Imvanex vaccine to the US Government and has already supplied the vaccine in the European Union (EU) to many different, often unnamed, European countries. Bavarian Nordic is focused on developing, manufacturing, and commercializing human vaccines. Imvanex vaccine has been authorized to protect adults from MPX disease in the EU since 22nd July 2022.

Since the time of vaccine approval, the region has been ramping up to supply vaccine doses to every country dealing with the highest number of cases. Vaccine administration and contact tracing have rapidly increased in Spain, the second country after the US, with the highest number of confirmed cases since June 2022. On 20th October 2022, National Health Service (NHS) launched a new online vaccine site finder to make it easy for eligible people to vaccinate.

REGIONAL ANALYSIS

In 2022, EU-5 accounted for the largest share of 77.71% in the Europe monkeypox testing market. In EU-5, Spain accounts for the highest revenue share, followed by France, UK, Germany, and Italy, which can be attributed to increasing cases, and increased testing. More than 98% of cases are identified in men who have sex with men in EU-5. The Netherlands is vaccinating high-risk people against MPX using two doses of the Imvanex smallpox vaccine. Until 3rd August 2022, 1,976 people in the Netherlands received a preventive vaccination against the MPXV.

In Berlin, Germany, vaccinations against the viral infection had begun in mid-July. In July, The Standing Commission on Vaccination (Stiko) recommended this for certain groups and people who have had close contact with infected persons. It sees an increased risk of infection, particularly among men who have same-sex sexual contact with changing partners. According to the Senate Department for Health, demand for the MPX vaccine is very high in Berlin; however, the vaccine is still in very short supply. The shortage in vaccine supply has increased the chances of spreading MPX, which implicitly increases the possibilities of the Europe monkeypox testing market growth. However, in the future, the growing number of vaccinations for monkeypox may hinder the growth of the MPX testing market. In addition, as the currently authorized vaccine, Imvanex is not authorized for children and pregnant women, the growth of MPX testing still holds growth opportunities during the forecast period. Also, an increase in risky behavior may cause a resurgence of the virus that may keep the opportunity for MPX testing market demand.

Segmentation By Region

  • Europe
    • EU-5
  • Spain
  • France
  • UK
  • Germany
  • Italy
    • Central, Eastern, and Southern Europe
  • Netherlands
  • Portugal
  • Switzerland
    • Nordic
  • Sweden
  • Denmark

VENDOR LANDSCAPE

  • Hoffmann-La Roche
  • Qiagen
  • altona Diagnostics
  • Autobio
  • Applied DNA Sciences
  • Aurora Biomed
  • bioactiva diagnostica
  • Beijing Hotgen Biotech
  • BioGX
  • CERTEST BIOTEC
  • Creative Biogene
  • CorDx
  • CLONIT
  • Eurobio Scientific
  • FireGene
  • GenScript
  • Guangzhou Pluslife Biotech
  • JOYSBIO (Tianjin) Biotechnology
  • Nanjing Synthgene Medical Technology
  • RayBiotech Life
  • Sansure Biotech
  • Virax Biolabs
  • Wondfo
  • Shanghai Biogerm Medical Technology

KEY QUESTIONS ANSWERED

How big is the Europe monkeypox testing market?

What is the projected growth rate of the Europe monkeypox testing market during the forecast period?

What are the growing trends in the Europe monkeypox testing market?

Which region holds the largest Europe monkeypox testing market share?

Which are the key players in the Europe monkeypox testing market?

Product Code: ARZ230120

TABLE OF CONTENTS

1 RESEARCH METHODOLOGY

2 RESEARCH OBJECTIVES

3 RESEARCH PROCESS

4 SCOPE & COVERAGE

  • 4.1 MARKET DEFINITION
    • 4.1.1 INCLUSIONS
    • 4.1.2 EXCLUSIONS
    • 4.1.3 MARKET ESTIMATION CAVEATS
  • 4.2 BASE YEAR
  • 4.3 SCOPE OF THE STUDY
    • 4.3.1 MARKET SEGMENTATION BY TYPE
    • 4.3.2 MARKET SEGMENTATION BY END-USER
    • 4.3.3 MARKET SEGMENTATION BY GEOGRAPHY

5 REPORT ASSUMPTIONS & CAVEATS

  • 5.1 KEY CAVEATS
  • 5.2 CURRENCY CONVERSION
  • 5.3 MARKET DERIVATION

6 PREMIUM INSIGHTS

  • 6.1 OVERVIEW

7 MARKET AT A GLANCE

8 INTRODUCTION

  • 8.1 OVERVIEW

9 MARKET OPPORTUNITIES & TRENDS

  • 9.1 DEVELOPMENT OF RAPID TESTING METHODS
  • 9.2 ADVANCES IN PCR TECHNOLOGY
  • 9.3 VENDOR COLLABORATIONS

10 MARKET GROWTH ENABLERS

  • 10.1 INCREASED GOVERNMENT SURVEILLANCE
  • 10.2 EASE OF REGULATIONS FOR PRODUCT APPROVALS
  • 10.3 INCREASED PRODUCT LAUNCHES

11 MARKET RESTRAINTS

  • 11.1 DECLINE IN MPX CASES
  • 11.2 MPX VACCINE APPROVAL & ACCESS
  • 11.3 FALSE MPX TEST RESULTS

12 MARKET LANDSCAPE

  • 12.1 MARKET OVERVIEW
    • 12.1.1 INSIGHTS BY TYPE
    • 12.1.2 INSIGHTS BY END-USER
    • 12.1.3 INSIGHTS BY GEOGRAPHY
  • 12.2 FIVE FORCES ANALYSIS
    • 12.2.1 THREAT OF NEW ENTRANTS
    • 12.2.2 BARGAINING POWER OF SUPPLIERS
    • 12.2.3 BARGAINING POWER OF BUYERS
    • 12.2.4 THREAT OF SUBSTITUTES
    • 12.2.5 COMPETITIVE RIVALRY

13 TEST TYPE

  • 13.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 13.2 MARKET OVERVIEW
  • 13.3 PCR
    • 13.3.1 MARKET OVERVIEW
    • 13.3.2 MARKET SIZE & FORECAST
  • 13.4 LATERAL FLOW ASSAYS
    • 13.4.1 MARKET OVERVIEW
    • 13.4.2 MARKET SIZE & FORECAST
  • 13.5 OTHERS
    • 13.5.1 MARKET OVERVIEW
    • 13.5.2 MARKET SIZE & FORECAST

14 END-USER

  • 14.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 14.2 MARKET OVERVIEW
  • 14.3 LABORATORIES
    • 14.3.1 MARKET OVERVIEW
    • 14.3.2 MARKET SIZE & FORECAST
  • 14.4 HOSPITALS & CLINICS
    • 14.4.1 MARKET OVERVIEW
    • 14.4.2 MARKET SIZE & FORECAST
  • 14.5 OTHERS
    • 14.5.1 MARKET OVERVIEW
    • 14.5.2 MARKET SIZE & FORECAST

15 GEOGRAPHY

  • 15.1 MARKET SNAPSHOT & GROWTH ENGINE
  • 15.2 MARKET OVERVIEW

16 EU-5

  • 16.1 MARKET OVERVIEW
  • 16.2 MARKET SIZE & FORECAST
  • 16.3 KEY COUNTRIES
    • 16.3.1 SPAIN: MARKET SIZE & FORECAST
    • 16.3.2 FRANCE: MARKET SIZE & FORECAST
    • 16.3.3 UK: MARKET SIZE & FORECAST
    • 16.3.4 GERMANY: MARKET SIZE & FORECAST
    • 16.3.5 ITALY: MARKET SIZE & FORECAST

17 CENTRAL, EASTERN & SOUTHERN EUROPE

  • 17.1 MARKET OVERVIEW
  • 17.2 MARKET SIZE & FORECAST
  • 17.3 KEY COUNTRIES
    • 17.3.1 NETHERLANDS: MARKET SIZE & FORECAST
    • 17.3.2 PORTUGAL: MARKET SIZE & FORECAST
    • 17.3.3 SWITZERLAND: MARKET SIZE & FORECAST

18 NORDICS

  • 18.1 MARKET OVERVIEW
  • 18.2 MARKET SIZE & FORECAST
  • 18.3 KEY COUNTRIES
    • 18.3.1 SWEDEN: MARKET SIZE & FORECAST
    • 18.3.2 DENMARK: MARKET SIZE & FORECAST

19 COMPETITIVE LANDSCAPE

  • 19.1 COMPETITION OVERVIEW
  • 19.2 MARKET SHARE ANALYSIS
    • 19.2.1 F. HOFFMANN-LA ROCHE
    • 19.2.2 QIAGEN

20 KEY COMPANY PROFILES

  • 20.1 F. HOFFMANN-LA ROCHE
    • 20.1.1 BUSINESS OVERVIEW
    • 20.1.2 PRODUCT OFFERINGS
    • 20.1.3 KEY STRATEGIES
    • 20.1.4 KEY STRENGTHS
    • 20.1.5 KEY OPPORTUNITIES
  • 20.2 QIAGEN
    • 20.2.1 BUSINESS OVERVIEW
    • 20.2.2 PRODUCT OFFERINGS
    • 20.2.3 KEY STRATEGIES
    • 20.2.4 KEY STRENGTHS
    • 20.2.5 KEY OPPORTUNITIES

21 OTHER PROMINENT VENDORS

  • 21.1 ALTONA DIAGNOSTICS
    • 21.1.1 BUSINESS OVERVIEW
    • 21.1.2 PRODUCT OFFERINGS
  • 21.2 AUTOBIO
    • 21.2.1 BUSINESS OVERVIEW
    • 21.2.2 PRODUCT OFFERINGS
  • 21.3 APPLIED DNA SCIENCES
    • 21.3.1 BUSINESS OVERVIEW
    • 21.3.2 PRODUCT OFFERINGS
  • 21.4 AURORA BIOMED
    • 21.4.1 BUSINESS OVERVIEW
    • 21.4.2 PRODUCT OFFERINGS
  • 21.5 BIOACTIVA DIAGNOSTICA
    • 21.5.1 BUSINESS OVERVIEW
    • 21.5.2 PRODUCT OFFERINGS
  • 21.6 BEIJING HOTGEN BIOTECH
    • 21.6.1 BUSINESS OVERVIEW
    • 21.6.2 PRODUCT OFFERINGS
  • 21.7 BIOGX
    • 21.7.1 BUSINESS OVERVIEW
    • 21.7.2 PRODUCT OFFERINGS
  • 21.8 CERTEST BIOTEC
    • 21.8.1 BUSINESS OVERVIEW
    • 21.8.2 PRODUCT OFFERINGS
  • 21.9 CREATIVE BIOGENE
    • 21.9.1 BUSINESS OVERVIEW
    • 21.9.2 PRODUCT OFFERINGS
  • 21.10 CORDX
    • 21.10.1 BUSINESS OVERVIEW
    • 21.10.2 PRODUCT OFFERINGS
  • 21.11 CLONIT
    • 21.11.1 BUSINESS OVERVIEW
    • 21.11.2 PRODUCT OFFERINGS
  • 21.12 EUROBIO SCIENTIFIC
    • 21.12.1 BUSINESS OVERVIEW
    • 21.12.2 PRODUCT OFFERINGS
  • 21.13 FIREGENE
    • 21.13.1 BUSINESS OVERVIEW
    • 21.13.2 PRODUCT OFFERINGS
  • 21.14 GENSCRIPT
    • 21.14.1 BUSINESS OVERVIEW
    • 21.14.2 PRODUCT OFFERINGS
  • 21.15 GUANGZHOU PLUSLIFE BIOTECH
    • 21.15.1 BUSINESS OVERVIEW
    • 21.15.2 PRODUCT OFFERINGS
  • 21.16 JOYSBIO (TIANJIN) BIOTECHNOLOGY
    • 21.16.1 BUSINESS OVERVIEW
    • 21.16.2 PRODUCT OFFERINGS
  • 21.17 NANJING SYNTHGENE MEDICAL TECHNOLOGY
    • 21.17.1 BUSINESS OVERVIEW
    • 21.17.2 PRODUCT OFFERINGS
  • 21.18 RAYBIOTECH LIFE
    • 21.18.1 BUSINESS OVERVIEW
    • 21.18.2 PRODUCT OFFERINGS
  • 21.19 SANSURE BIOTECH
    • 21.19.1 BUSINESS OVERVIEW
    • 21.19.2 PRODUCT OFFERINGS
  • 21.20 VIRAX BIOLABS
    • 21.20.1 BUSINESS OVERVIEW
    • 21.20.2 PRODUCT OFFERINGS
  • 21.21 WONDFO
    • 21.21.1 BUSINESS OVERVIEW
    • 21.21.2 PRODUCT OFFERINGS
  • 21.22 SHANGHAI BIOGERM MEDICAL TECHNOLOGY
    • 21.22.1 BUSINESS OVERVIEW
    • 21.22.2 PRODUCT OFFERINGS

22 REPORT SUMMARY

  • 22.1 KEY TAKEAWAYS
  • 22.2 STRATEGIC RECOMMENDATIONS

23 QUANTITATIVE SUMMARY

  • 23.1 MARKET BY GEOGRAPHY
  • 23.2 MARKET BY TYPE
  • 23.3 MARKET BY END-USER

24 APPENDIX

  • 24.1 ABBREVIATIONS
Product Code: ARZ230120

LIST OF EXHIBITS

  • EXHIBIT 1 SEGMENTATION OF EUROPE MONKEYPOX TESTING MARKET
  • EXHIBIT 2 MARKET SIZE CALCULATION APPROACH 2022
  • EXHIBIT 3 TESTING ALGORITHM FOR MPX VIRUS
  • EXHIBIT 4 IMPACT OF DEVELOPMENT OF RAPID TESTING METHODS
  • EXHIBIT 5 POPULAR RAPID TEST KITS
  • EXHIBIT 6 IMPACT OF ADVANCES IN PCR TECHNOLOGY
  • EXHIBIT 7 IMPACT OF VENDOR COLLABORATIONS
  • EXHIBIT 8 IMPACT OF INCREASED GOVERNMENT SURVEILLANCE
  • EXHIBIT 9 IMPACT OF EASE OF REGULATIONS FOR PRODUCT APPROVALS
  • EXHIBIT 10 IMPACT OF INCREASED PRODUCT LAUNCHES
  • EXHIBIT 11 IMPACT OF DECLINE IN MPX CASES
  • EXHIBIT 12 IMPACT OF MPX VACCINE APPROVAL & ACCESS
  • EXHIBIT 13 GLOBAL QUARTER SALES OF IMVANEX, 2022 ($ MILLION)
  • EXHIBIT 14 IMPACT OF FALSE MPX TEST RESULTS
  • EXHIBIT 15 GROWTH CURVE OF MPX CASES IN EUROPE AS OF NOVEMBER 7, 2022
  • EXHIBIT 16 PERCENT DISTRIBUTION OF DATA TYPE IN EUROPE AS OF NOVEMBER 9, 2022
  • EXHIBIT 17 EUROPE MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 18 EUROPE MONKEYPOX TESTING MARKET BY TYPE 2022-2025 (%)
  • EXHIBIT 19 EUROPE MONKEYPOX TESTING MARKET BY END-USER 2022-2025 (%)
  • EXHIBIT 20 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY 2022-2025 (%)
  • EXHIBIT 21 FIVE FORCES ANALYSIS 2022
  • EXHIBIT 22 INCREMENTAL GROWTH BY TYPE 2022 & 2025
  • EXHIBIT 23 EUROPE MONKEYPOX TESTING MARKET BY TYPE
  • EXHIBIT 24 EUROPE MONKEYPOX TESTING MARKET BY TYPE: INCREMENTAL GROWTH ($ THOUSAND)
  • EXHIBIT 25 EUROPE MONKEYPOX TESTING MARKET BY TYPE: ABSOLUTE GROWTH (%)
  • EXHIBIT 26 EUROPE MONKEYPOX TESTING MARKET BY PCR 2022-2025 ($ THOUSAND)
  • EXHIBIT 27 EUROPE MONKEYPOX TESTING MARKET BY PCR: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 28 EUROPE MONKEYPOX TESTING MARKET BY LATERAL FLOW ASSAYS 2022-2025 ($ THOUSAND)
  • EXHIBIT 29 EUROPE MONKEYPOX TESTING MARKET BY LATERAL FLOW ASSAYS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 30 EUROPE MONKEYPOX TESTING MARKET BY OTHERS 2022-2025 ($ THOUSAND)
  • EXHIBIT 31 EUROPE MONKEYPOX TESTING MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 32 INCREMENTAL GROWTH BY END-USER 2022 & 2025
  • EXHIBIT 33 EUROPE MONKEYPOX TESTING MARKET BY END-USER
  • EXHIBIT 34 EUROPE MONKEYPOX TESTING MARKET BY END-USER: INCREMENTAL GROWTH ($ THOUSAND)
  • EXHIBIT 35 EUROPE MONKEYPOX TESTING MARKET BY END-USER: ABSOLUTE GROWTH (%)
  • EXHIBIT 36 EUROPE MONKEYPOX TESTING MARKET BY LABORATORIES: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 37 EUROPE MONKEYPOX TESTING MARKET BY LABORATORIES 2022-2025 ($ THOUSAND)
  • EXHIBIT 38 EUROPE MONKEYPOX TESTING MARKET BY HOSPITALS & CLINICS 2022-2025 ($ THOUSAND)
  • EXHIBIT 39 EUROPE MONKEYPOX TESTING MARKET BY HOSPITALS & CLINICS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 40 NEW PRODUCT LAUNCHES
  • EXHIBIT 41 EUROPE MONKEYPOX TESTING MARKET BY OTHERS 2022-2025 ($ THOUSAND)
  • EXHIBIT 42 EUROPE MONKEYPOX TESTING MARKET BY OTHERS: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 43 INCREMENTAL GROWTH BY GEOGRAPHY 2022 & 2025
  • EXHIBIT 44 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY
  • EXHIBIT 45 NUMBER OF MPX CASES IN EUROPEAN COUNTRIES AS OF NOVEMBER 9, 2022
  • EXHIBIT 46 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY: INCREMENTAL GROWTH ($ THOUSAND)
  • EXHIBIT 47 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY: ABSOLUTE GROWTH (%)
  • EXHIBIT 48 EUROPE MONKEYPOX TESTING MARKET: KEY COUNTRIES 2022 ($ THOUSAND)
  • EXHIBIT 49 NUMBER OF MPX CASES IN EU-5 AS OF NOVEMBER 9, 2022
  • EXHIBIT 50 EU-5 MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 51 EU-5 MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 52 INCREMENTAL GROWTH IN EU-5 2022 & 2025
  • EXHIBIT 53 SPAIN MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 54 FRANCE MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 55 UK MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 56 GERMANY MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 57 ITALY MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 58 TOP COUNTRIES WITH MPX CASES IN CENTRAL, EASTERN & SOUTHERN EUROPE AS OF NOVEMBER 9, 2022
  • EXHIBIT 59 CENTRAL, EASTERN & SOUTHERN EUROPE MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 60 CENTRAL, EASTERN & SOUTHERN EUROPE MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 61 INCREMENTAL GROWTH IN CENTRAL, EASTERN & SOUTHERN EUROPE 2022 & 2025
  • EXHIBIT 62 NETHERLANDS MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 63 PORTUGAL MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 64 SWITZERLAND TOTAL MONKEYPOX CASES AS OF NOVEMBER 7, 2022
  • EXHIBIT 65 SWITZERLAND MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 66 TOP NORDIC COUNTRIES WITH MPX CASES AS OF NOVEMBER 9, 2022
  • EXHIBIT 67 NORDICS MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 68 NORDICS MONKEYPOX TESTING MARKET: INCREMENTAL & ABSOLUTE GROWTH
  • EXHIBIT 69 INCREMENTAL GROWTH IN NORDICS 2022 & 2025
  • EXHIBIT 70 SWEDEN MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)
  • EXHIBIT 71 DENMARK MONKEYPOX TESTING MARKET 2022-2025 ($ THOUSAND)

LIST OF TABLES

  • TABLE 1 KEY CAVEATS
  • TABLE 2 CURRENCY CONVERSION 2015-2022
  • TABLE 3 MOLECULAR TECHNIQUES FOR NUCLEIC ACID DETECTION
  • TABLE 4 IMMUNOLOGICAL METHODS FOR ANTIBODY OR ANTIGEN DETECTION
  • TABLE 5 TOTAL MPX CASES AMONG MEN FROM DIFFERENT CATEGORIES AS OF NOVEMBER 9, 2022
  • TABLE 6 RECENT MONKEYPOX TEST LAUNCHES
  • TABLE 7 SUMMARY OF MONKEYPOX CASES AS OF NOVEMBER 8, 2022
  • TABLE 8 NEWLY LAUNCHED PCR KITS WITH CE CERTIFICATION
  • TABLE 9 COMPANIES THAT OFFER LATERAL FLOW ASSAY KITS
  • TABLE 10 F. HOFFMANN-LA ROCHE: MAJOR PRODUCT OFFERINGS
  • TABLE 11 QIAGEN: MAJOR PRODUCT OFFERINGS
  • TABLE 12 ALTONA DIAGNOSTICS: MAJOR PRODUCT OFFERINGS
  • TABLE 13 AUTOBIO: MAJOR PRODUCT OFFERINGS
  • TABLE 14 APPLIED DNA SCIENCES: MAJOR PRODUCT OFFERINGS
  • TABLE 15 AURORA BIOMED: MAJOR PRODUCT OFFERINGS
  • TABLE 16 BIOACTIVA DIAGNOSTICA: MAJOR PRODUCT OFFERINGS
  • TABLE 17 BEIJING HOTGEN BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 18 BIOGX: MAJOR PRODUCT OFFERINGS
  • TABLE 19 CERTEST BIOTEC: MAJOR PRODUCT OFFERINGS
  • TABLE 20 CREATIVE BIOGENE: MAJOR PRODUCT OFFERINGS
  • TABLE 21 CORDX: MAJOR PRODUCT OFFERINGS
  • TABLE 22 CLONIT: MAJOR PRODUCT OFFERINGS
  • TABLE 23 EUROBIO SCIENTIFIC: MAJOR PRODUCT OFFERINGS
  • TABLE 24 FIREGENE: MAJOR PRODUCT OFFERINGS
  • TABLE 25 GENSCRIPT: MAJOR PRODUCT OFFERINGS
  • TABLE 26 GUANGZHOU PLUSLIFE BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 27 JOYSBIO (TIANJIN) BIOTECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 28 NANJING SYNTHGENE MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 29 RAYBIOTECH LIFE: MAJOR PRODUCT OFFERINGS
  • TABLE 30 SANSURE BIOTECH: MAJOR PRODUCT OFFERINGS
  • TABLE 31 VIRAX BIOLABS: MAJOR PRODUCT OFFERINGS
  • TABLE 32 WONDFO: MAJOR PRODUCT OFFERINGS
  • TABLE 33 SHANGHAI BIOGERM MEDICAL TECHNOLOGY: MAJOR PRODUCT OFFERINGS
  • TABLE 34 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY 2022-2025 ($ THOUSAND)
  • TABLE 35 EUROPE MONKEYPOX TESTING MARKET BY GEOGRAPHY 2022-2025 (%)
  • TABLE 36 EUROPE MONKEYPOX TESTING MARKET BY TYPE 2022-2025 ($ THOUSAND)
  • TABLE 37 EUROPE MONKEYPOX TESTING MARKET BY TYPE 2022-2025 (%)
  • TABLE 38 EUROPE MONKEYPOX TESTING MARKET BY END-USER 2022-2025 ($ THOUSAND)
  • TABLE 39 EUROPE MONKEYPOX TESTING MARKET BY END-USER 2022-2025 (%)
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!